Physician profile
Monica Ramirez
NPI 1578950036
$8,980.93
in general payments reported to CMS, 2019-2025
46 companies · $1,913 in 2025
The $1,913 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $629 · 2021: $911 · 2022: $1,434 · 2023: $1,722 · 2024: $1,616 · 2025: $1,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,121 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,120.81 |
| Education | $129.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,035.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $880.66 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $849.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Gilead Sciences, INC. | $810.58 | 2019-2025 | |
| Abbvie INC. | $572.14 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.51 | 2019-2025 | Jardiance, Glyxambi, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $500.66 | 2019-2024 | Farxiga |
| Abbott Laboratories | $439.49 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $405.11 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $333.18 | 2020-2025 | Spravato |
| Merck Sharp & Dohme LLC | $329.53 | 2020-2024 | Verquvo, Belsomra, Capvaxive |
| Amgen INC. | $246.70 | 2019-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $168.45 | 2024-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $161.76 | 2024-2025 | Auvelity |
| Viiv Healthcare Company | $147.71 | 2019-2025 | Apretude |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.